PolyPeptide Group AG (SWX:PPGN)

Switzerland · Delayed Price · Currency is CHF

23.75

-1.10 (-4.43%)

At close: Mar 6, 2026

23.70% (1Y)

Market Cap	783.55M
Revenue (ttm)	344.49M
Net Income (ttm)	-32.42M
Shares Out	32.99M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,405
Average Volume	41,618
Open	24.65
Previous Close	24.85
Day's Range	23.40 - 24.80
52-Week Range	13.22 - 32.70
Beta	1.08
RSI	36.24
Earnings Date	Mar 12, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 195... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1952

Employees 1,400

Stock Exchange SIX Swiss Exchange

Ticker Symbol PPGN

Full Company Profile

Financial Performance

In 2024, PolyPeptide Group AG's revenue was 336.79 million, an increase of 5.13% compared to the previous year's 320.37 million. Losses were -19.56 million, -61.97% less than in 2023.

Financial numbers in EUR Financial Statements

PolyPeptide Group AG (SWX:PPGN)

About PolyPeptide Group AG

Financial Performance

News

PolyPeptide Reports Strong Preliminary 2025 Results With Higher Revenue And Profit

PolyPeptide Group AG (PLYGF) Reports FY Revenue of EUR 389M

Lupin subsidiary forms long-term strategic alliance with PolyPeptide Group to strengthen global peptide supply chain